Search Result

Results for "

reabsorption

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino acid Transporter (2) Anion Exchangers (1) Apical Sodium-Dependent Bile Acid Transporter (2) Biochemical Assay Reagents (3) Carbonic Anhydrase (3) Chloride Channel (2) Drug Derivative (1) Drug Metabolite (2) Endogenous Metabolite (3) Endothelin Receptor (1) Environmental Pollutants (1) Ferroptosis (1) Fungal (1) GLUT (1) Interleukin Related (1) Keap1-Nrf2 (1) Na+/H+ Exchanger (NHE) (1) Natriuretic Peptide Receptor (NPR) (1) Opioid Receptor (2) Reference Standards (5) ROS Kinase (1) SGLT (5) Sodium Channel (3) Toll-like Receptor (TLR) (1) URAT1 (1) Vasopressin Receptor (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (12) Infection (1) Inflammation/Immunology (2) Metabolic Disease (23) Neurological Disease (2)

By Targets:

Amino acid Transporter (2)

Anion Exchangers (1)

Apical Sodium-Dependent Bile Acid Transporter (2)

Biochemical Assay Reagents (3)

Carbonic Anhydrase (3)

Chloride Channel (2)

Drug Derivative (1)

Drug Metabolite (2)

Endogenous Metabolite (3)

Endothelin Receptor (1)

Environmental Pollutants (1)

Ferroptosis (1)

Fungal (1)

GLUT (1)

Interleukin Related (1)

Keap1-Nrf2 (1)

Na+/H+ Exchanger (NHE) (1)

Natriuretic Peptide Receptor (NPR) (1)

Opioid Receptor (2)

Reference Standards (5)

ROS Kinase (1)

SGLT (5)

Sodium Channel (3)

Toll-like Receptor (TLR) (1)

URAT1 (1)

Vasopressin Receptor (1)

By Research Areas:

Cancer (3)

Cardiovascular Disease (12)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (23)

Neurological Disease (2)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0080

Aminohippurate sodium 4 Publications Verification Sodium p-aminohippurate; p-Aminohippuric acid sodium salt	Biochemical Assay Reagents
Aminohippurate sodium is a renal tubular transport inhibitor and a substrate for organic anion transporters. Aminohippurate sodium inhibits renal tubular reabsorption of phosphate and promotes increased urinary phosphate excretion. Aminohippurate sodium inhibits renal tubular reabsorption of vitamin C as well as the transport of glucose .

HY-A0118A

Naloxegol oxalate 2 Publications Verification NKTR-118 oxalate; AZ-13337019 oxalate	Opioid Receptor	Metabolic Disease
Naloxegol oxalate (NKTR-118 oxalate; AZ-13337019 oxalate) is an orally active peripherally acting μ-opioid receptor antagonist with a target K_i of 7.42 nM. Naloxegol oxalate inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol oxalate is applicable to research related to opioid-induced constipation .

HY-B0908

Meticrane 2 Publications Verification	Sodium Channel Chloride Channel	Cardiovascular Disease
Meticrane is a diuretic. Meticrane inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension.

HY-W042301

Xipamide	Anion Exchangers Carbonic Anhydrase Endothelin Receptor	Cardiovascular Disease
Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na ⁺/Cl ^--potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl ^-/NaCO₃ ^- anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca ²⁺ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .

HY-N15135

Arabinoxylan (Medium viscosity)	Interleukin Related Toll-like Receptor (TLR) Fungal	Metabolic Disease
Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome .

HY-156696

S3226	Na+/H+ Exchanger (NHE)	Metabolic Disease
S3226 is a highly selective NHE-3 inhibitor (IC₅₀<1 μM) that specifically blocks NHE-3-mediated sodium transport. S3226 significantly inhibits blastocyst formation and expansion in mouse embryos, and reduces fluid and electrolyte reabsorption in rat proximal tubules in a dose-dependent manner. S3226 effectively alleviates ischemia-induced acute renal failure by improving renal function parameters, reducing renal tubular injury and restoring intracellular pH homeostasis, without interfering with the normal tubuloglomerular feedback response. S3226 is widely used in studies of acute renal failure and related pathological mechanisms .

HY-162864

JX237	Amino acid Transporter	Metabolic Disease
JX237 is an inhibitor of the epithelial neutral amino acid transporter B ⁰AT1 (SLC6A19) with an IC₅₀ value of 31 nM. SLC6A19 is the main transporter for the absorption of neutral amino acids in the intestines and their reabsorption in the kidneys. By inhibiting B ⁰AT1, JX237 can be used for the study of disorders of amino acid metabolism .

HY-148795

Ritivixibat	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Ritivixibat is an apical sodium-dependent bile acid transporter (ASBT/IBAT) inhibitor. Ritivixibat blocks ASBT/IBAT function, thereby reducing bile acid reabsorption, regulating bile acid homeostasis and alleviating liver injury. Ritivixibat protects cholangiocytes from damage caused by cytotoxic bile acids. Ritivixibat is applicable to research related to primary sclerosing cholangitis .

HY-W013266

N4-Acetylsulfamethoxazole Acetylsulfamethoxazole	Drug Metabolite	Infection Metabolic Disease
N4-Acetylsulfamethoxazole (Acetylsulfamethoxazole) is the N4-acetylated metabolite of Sulfamethoxazole (HY-B0322) .

HY-N0394R

L-Cystine (Standard)	Reference Standards Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2	Metabolic Disease Inflammation/Immunology Cancer
L-Cystine (Standard) is the analytical standard of L-Cystine. This product is intended for research and analytical applications. L-Cystine, the extracellular form of L-Cysteine (HY-Y0337), is a nutritionally dispensable semiessential sulfur-containing amino acid, occurring in proteins of plants and animals. L-Cystine induces Nrf2 protein elevation in a Keap1 (HY-P75897)-dependent manner and activates Nrf2 transcription factor. L-cystine can elicit cytoprotection by reducing ROS generation and protecting against oxidant- or doxorubicin-induced apoptosis. The reduced reabsorption of L-Cystine in renal tubules and its poor solubility in urine are the important causes of cystine precipitation and cystine crystal formation eventually leading to kidney stones. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and cystinosis

HY-109542

Cyclopenthiazide	Biochemical Assay Reagents	Metabolic Disease
Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney .

HY-109018B

Velagliflozin proline hydrate 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-179107

SLC6A19-IN-3	Amino acid Transporter	Metabolic Disease
SLC6A19-IN-3 (Compound 83-P1-P2) is a potent, selective and orally active SLC6A19 inhibitor with an IC₅₀ of 28 nM. SLC6A19-IN-3 can block SLC6A19-mediated transmembrane transport of phenylalanine, reducing intestinal absorption of phenylalanine from food and renal tubular reabsorption of phenylalanine. SLC6A19-IN-3 can be used for the research of metabolic disease, such as phenylketonuria .

HY-A0118

Naloxegol NKTR-118; AZ-13337019	Opioid Receptor	Neurological Disease Cancer
Naloxegol (NKTR-118; AZ-13337019) is an orally active peripherally acting μ-opioid receptor antagonist with a target K_i of 7.42 nM. Naloxegol inhibits the binding of opioids to μ-opioid receptors in the gastrointestinal tract, and alleviates opioid-induced gastrointestinal hypomotility, delayed transit, hypertonicity, and increased fluid reabsorption. Naloxegol is applicable to research related to opioid-induced constipation .

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-B2081

Etozolin W-2900A	Others	Cardiovascular Disease Metabolic Disease
Etozolin (W-2900A) is a diuretic agent. Etozolin inhibits fluid and electrolyte reabsorption in the loop of Henle. Etozolin can be used in research of congestive heart failure, hypertension and edema .

HY-137364

Disulfamide	Carbonic Anhydrase	Cardiovascular Disease Metabolic Disease
Disulfamide, an orally active diuretic, is a carbonic anhydrase inhibitor with the IC₅₀ value of 0.07 μM. Disulfamide leads to diuresis by inhibiting carbonic anhydrase and preventing the reabsorption of sodium and bicarbonate in the proximal tubule .

HY-B0908R

Meticrane (Standard)	Reference Standards Sodium Channel Chloride Channel	Cardiovascular Disease
Meticrane (Standard) is the analytical standard of Meticrane. This product is intended for research and analytical applications. Meticrane is a diuretic. Meticrane inhibits the reabsorption of sodium and chloride ions in the distal convoluted tubule. Meticrane is used to treat essential hypertension.

HY-120147

Ethiazide	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Ethiazide is a thiazole diuretic which inhibits renal reabsorption of sodium and water, thereby increasing urine excretion, reducing fluid retention, and lowering blood volume and blood pressure. Ethiazide can be used for cardiovascular research .

HY-109542R

Cyclopenthiazide (Standard)	Biochemical Assay Reagents Reference Standards	Metabolic Disease
Cyclopenthiazide (Standard) is the analytical standard of Cyclopenthiazide. This product is intended for research and analytical applications. Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney .

HY-165423

DM-4111	Vasopressin Receptor Drug Metabolite	Cardiovascular Disease
DM-4111, one of the major monohydroxyl metabolites of Tolvaptan (HY-17000), is a potent vasopressin V₂ receptor inhibitor. DM-4111 inhibits water reabsorption in the renal tubules, thereby promoting the excretion of electrolyte-free water. DM-4111 is promising for research of cardiovascular diseases .

HY-N13218

Pueraria Extract	Others	Cardiovascular Disease
Pueraria Extract is a kudzu extract, and its components include: Isoflavones. Pueraria Extract (ethanol extract) can significantly improve cardiac damage in rats with acute myocardial infarction. Pueraria Extract improves bile acid levels by increasing the expression of CYP7A1 and restoring the diversity of intestinal microbiota. Pueraria Extract can also inhibit the FXR-FGF15 signaling pathway and increase the expression of OST-α to increase bile acid reabsorption and fecal excretion. .

HY-134043

Chlorthalidone Impurity G Chlorthalidone EP Impurity G	Carbonic Anhydrase	Cardiovascular Disease
Chlorthalidone Impurity G (Chlorthalidone EP Impurity G) is a potential impurity found in commercial preparations of chlorthalidone with moderate antihypertensive effects. Chlorthalidone is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal tubule of the kidney, thereby preventing sodium and chloride reabsorption, resulting in decreased plasma volume and cardiac output. It also inhibits carbonic anhydrase (CA), including isoenzymes CAVB, VII, IX, XII, and XIII (Kis=2.8-23 nM) and to a lesser extent CAI, CAII, IV, VA, and VI (Ki=138-1,347 nM), mediating vasodilatory activity.

HY-109018AR

Velagliflozin proline (Standard)	Reference Standards SGLT	Metabolic Disease
Velagliflozin proline (Standard) is the analytical standard of Velagliflozin (proline) (HY-109018A). This product is intended for research and analytical applications. Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-B2081A

Etozolin hydrochloride W-2900A hydrochloride	Endogenous Metabolite	Cardiovascular Disease Metabolic Disease
Etozolin hydrochloride is a diuretic agent. Etozolin hydrochloride inhibits fluid and electrolyte reabsorption in the loop of Henle. Etozolin hydrochloride can be used in research of congestive heart failure, hypertension and edema .

HY-183658

URAT1/GLUT9-IN-3	URAT1 GLUT	Metabolic Disease Inflammation/Immunology
URAT1/GLUT9-IN-3 is an orally active URAT1/GLUT9 dual inhibitor with IC₅₀ values of 4.01 and 1.60 μM. URAT1/GLUT9-IN-3 inhibits URAT1-mediated uric acid uptake and GLUT9-mediated uric acid transport, reducing renal urate reabsorption. URAT1/GLUT9-IN-3 reduces serum uric acid levels in hyperuricemic mice. URAT1/GLUT9-IN-3 can be used for the researches of gout and hyperuricemia .

HY-Y0282

Sodium bromide NSC 77384; Sanibrom 40	Environmental Pollutants	Neurological Disease
Sodium bromide (NSC 77384; Sanibrom 40) is a GABA-ergic system modulator that crosses the blood-brain barrier, and it effectively reduces and blocks epileptiform discharges. Sodium bromide exerts significant anticonvulsant effects by enhancing GABA-ergic inhibitory functions, such as increasing the amplitude of inhibitory postsynaptic currents and paired-pulse inhibition. Sodium bromide specifically enhances stimulation-induced extracellular alkalosis without affecting baseline pH or subsequent acidosis processes. Sodium bromide exhibits species-specific pharmacokinetic characteristics, competes with chloride ions for renal tubular reabsorption sites, and serves as a marker for extracellular fluid volume. Sodium bromide can be used in the research of epilepsy and related neurological diseases .

HY-130301

Gallensre S 0960	Apical Sodium-Dependent Bile Acid Transporter	Metabolic Disease
Gallensre (S 0960) is an apical sodium-dependent bile acid transporter inhibitor (IC₅₀ = 5.8 μmol/L). Gallensre inhibits bile salt reabsorption in a rat model. Gallensre can be used to study metabolic diseases such as bile acid cycling .

HY-E70892

β-D-Glucuronidase, Bacteria	Endogenous Metabolite	Metabolic Disease
β-D-Glucuronidase, Bacteria (EC 3.2.1.31) catalyzes the breakdown of complex carbohydrates. β-D-Glucuronidase, Bacteria (EC 3.2.1.31) converts conjugated bilirubin into the unconjugated form, making bilirubin suitable for reabsorption.

HY-W587755

Benzylhydrochlorothiazide	Sodium Channel	Cardiovascular Disease
Benzylhydrochlorothiazide is an orally active thiazide diuretic. Benzylhydrochlorothiazide acts on the distal convoluted tubules of the kidneys, inhibiting the reabsorption of sodium chloride, thereby increasing urine output and reducing the body's fluid volume. Benzylhydrochlorothiazide has phototoxicity and a potential risk of skin reactions. Benzylhydrochlorothiazide can cause cell death when exposed to UVA radiation. Benzylhydrochlorothiazide is used in research on hypertension and edema .

HY-109018BR

Velagliflozin proline hydrate (Standard)	Reference Standards SGLT	Metabolic Disease
Velagliflozin proline hydrate (Standard) is the analytical standard of Velagliflozin (proline hydrate) (HY-109018B). This product is intended for research and analytical applications. Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-178734

Janagliflozin	SGLT	Metabolic Disease
Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC₅₀=0.0058 μM for SGLT2 and 4.802 μM for SGLT1). Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus .

HY-W343043

Pyrazinoylguanidine PZG	Drug Derivative	Cardiovascular Disease Metabolic Disease
Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride (HY-B0285). Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation .

Cat. No.	Product Name	Target	Research Area

HY-P10299

Calcitonin, porcine	Peptides	Others
Calcitonin, porcine inhibits 1,25 (OH)₂D₃-stimulated porcine osteoclast differentiation. Calcitonin is a polypeptide hormone that can lower serum calcium by decreasing calcium reabsorption in the kidney and inhibiting osteoclastic bone resorption. Calcitonin, porcine can be used for research of hypercalcemia .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9939

Burosumab 1 Publications Verification KRN23; N5KG1_C10_LH; UX-023	Inhibitory Antibodies	Metabolic Disease Cancer
Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N15135

Arabinoxylan (Medium viscosity)	Structural Classification Polysaccharides Antibiotics Leguminosae Pisum sativum Linn Plants Saccharides Other Antibiotics Source Classification	Interleukin Related Toll-like Receptor (TLR) Fungal
Arabinoxylan Medium viscosity is an orally active Dectin-1 splice variant modulator, glucose absorption inhibitor, and chyme viscosity enhancer. Arabinoxylan Medium viscosity inhibits particulate β-glucan-induced Dectin-1A activation and mildly suppresses Dectin-1B activation. In human dendritic cells stimulated with particulate β-glucan, Arabinoxylan Medium viscosity reduces the production of IL-10 and TNF-α, and increases the production of IL-4 and IL-23. Arabinoxylan Medium viscosity also supports antifungal immune responses without activating TLR2, TLR4 or TLR5, and does not induce cytokine production when used to stimulate human dendritic cells alone. Arabinoxylan Medium viscosity increases small intestinal chyme viscosity, gets degraded in the large intestine to produce short-chain fatty acids, reduces glucose absorption and insulin response, and improves glucose homeostasis. Arabinoxylan Medium viscosity supports microbial fermentation and the growth of beneficial microbiota in the gastrointestinal tract, prevents bile acid reabsorption, and delays starch digestion. Arabinoxylan Medium viscosity can be used in research related to type 2 diabetes, impaired glucose tolerance, and metabolic syndrome .

HY-N0394R

L-Cystine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Amino acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2
L-Cystine (Standard) is the analytical standard of L-Cystine. This product is intended for research and analytical applications. L-Cystine, the extracellular form of L-Cysteine (HY-Y0337), is a nutritionally dispensable semiessential sulfur-containing amino acid, occurring in proteins of plants and animals. L-Cystine induces Nrf2 protein elevation in a Keap1 (HY-P75897)-dependent manner and activates Nrf2 transcription factor. L-cystine can elicit cytoprotection by reducing ROS generation and protecting against oxidant- or doxorubicin-induced apoptosis. The reduced reabsorption of L-Cystine in renal tubules and its poor solubility in urine are the important causes of cystine precipitation and cystine crystal formation eventually leading to kidney stones. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and cystinosis

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks